4.7 Article

Migraine headache is present in the aura phase A prospective study

Journal

NEUROLOGY
Volume 79, Issue 20, Pages 2044-2049

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182749eed

Keywords

-

Funding

  1. NIH
  2. National Headache Foundation
  3. Migraine Research Fund
  4. CogniMed
  5. Scientiae
  6. Intramed
  7. SAGE Publishing
  8. Lippincott Williams Wilkins
  9. Oxford University Press
  10. Cambridge University Press
  11. Miller Medical
  12. Annenberg for Health Sciences
  13. Advanced Neurostimulation Systems
  14. Boston Scientific
  15. St Jude Medical, Inc.
  16. Medtronic
  17. National Institute of Neurological Disorders and Stroke/NIH
  18. Mayo Clinic
  19. AGA
  20. Capnia
  21. MAP
  22. Nu Pathe Merck
  23. GSK
  24. Eli Lilly
  25. GlaxoSmithKline
  26. Merck
  27. Allergan
  28. Cypress
  29. ANS
  30. MAP Pharma
  31. Depomed
  32. XLT
  33. Schwartz
  34. NuPathe
  35. Advanced Bionics
  36. Alexza
  37. MAP Pharmaceuticals
  38. Ortho-McNeil
  39. Neuralieve
  40. Takeda
  41. MSD
  42. Johnson Johnson
  43. eNeura
  44. Almirall
  45. ATI
  46. BMS
  47. Boehringer
  48. Coherex
  49. Colucid
  50. Lilly
  51. Minster
  52. NeurAxon
  53. NTP
  54. Pfizer
  55. International Headache Society
  56. Lundbeck Foundation
  57. Foundation of Ulla, Mogens Folmer Andersen
  58. Laegernes Forsikringsforening af 1891

Ask authors/readers for more resources

Objectives: Migraine aura is commonly considered to be a distinct phase of a migraine attack that precedes headache. The objective of the study was to examine a large number of prospectively recorded attacks of migraine with aura and determine the timing of headache and other migraine symptoms relative to aura. Methods: As part of a clinical trial we collected prospective data on the time course of headache and other symptoms relative to the aura. Patients (n = 267) were enrolled from 16 centers, and asked to keep a headache diary for 1 month (phase I). They were asked to record headache symptoms as soon as possible after aura began and always within 1 hour of aura onset. A total of 456 attacks were reported during phase I by 201 patients. These patients were then randomized and included in phase II, during which a total of 405 attacks were reported in 164 patients. In total, we present data from 861 attacks of migraine with aura from 201 patients. Results: During the aura phase, the majority of attacks (73%) were associated with headache. Other migraine symptoms were also frequently reported during the aura: nausea (51%), photophobia (88%), and photophobia (73%). During the first 15 minutes within the onset of aura, 54% of patients reported headache fulfilling the criteria for migraine. Conclusion: Our results indicate that headaches as well as associated migraine symptoms are present early, during the aura phase of the migraine attack in the majority of patients. Neurology (R) 2012; 79: 2044-2049

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available